BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238]
URL: https://www.wjgnet.com/1007-9327/full/v13/i39/5238.htm
Number Citing Articles
1
Abullah Alfawaz, Sultan Alrashidi, Hatem Kalantan, Hani Al-Mezaine, Ahmed M. Abu El-Asrar. Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet diseaseAnnals of Saudi Medicine 2014; 34(4): 328 doi: 10.5144/0256-4947.2014.328
2
Anita Annaházi, Tamás Molnár. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug WithdrawalGastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/832395
3
Walter Reinisch, William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Marion Blank, Yinghua Lang, Jewel Johanns, Jean Frédéric Colombel, Daniel Present, Bruce E. Sands. Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension StudiesInflammatory Bowel Diseases 2012; 18(2): 201 doi: 10.1002/ibd.21697
4
Nuray Uslu, Yusuf Usta, Inci Nur Saltik-Temizel, Hulya Demir, Figen Gürakan, Hasan Ozen, Aysel Yüce. Ineffectiveness of infliximab therapy in severe infantile Crohn's diseaseJournal of Crohn's and Colitis 2010; 4(1): 106 doi: 10.1016/j.crohns.2009.08.004
5
Tatsushi Kawaguchi, Yuko Kawazoe, Koju Kamoi, Masaru Miyanaga, Hiroshi Takase, Sunao Sugita, Manabu Mochizuki. Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapyJapanese Journal of Ophthalmology 2014; 58(1): 75 doi: 10.1007/s10384-013-0283-3
6
Daniel J Wong, Eve M Roth, Joseph D Feuerstein, Vitaliy Y Poylin. Surgery in the age of biologicsGastroenterology Report 2019; 7(2): 77 doi: 10.1093/gastro/goz004
7
W. Miehsler, G. Novacek, H. Wenzl, H. Vogelsang, P. Knoflach, A. Kaser, C. Dejaco, W. Petritsch, M. Kapitan, H. Maier, W. Graninger, H. Tilg, W. Reinisch. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel diseaseJournal of Crohn's and Colitis 2010; 4(3): 221 doi: 10.1016/j.crohns.2009.12.001
8
Melany Worbes-Cerezo, Beenish Nafees, Andrew Lloyd, Katy Gallop, Imran Ladha, Cicely Kerr. Disutility Study for Adult Patients with Moderate to Severe Crohn’s DiseaseJournal of Health Economics and Outcomes Research 2019; 6(2): 47 doi: 10.36469/9685
9
Sultan Al Rashidi, Abdullah Al Fawaz, Dustan Kangave, Ahmed M. Abu El-Asrar. Long-term Clinical Outcomes in Patients with Refractory Uveitis Associated with Behçet Disease Treated with InfliximabOcular Immunology and Inflammation 2013; 21(6): 468 doi: 10.3109/09273948.2013.779727
10
Michael B. Sprakes, Alexander C. Ford, Lisa Warren, Dan Greer, John Hamlin. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experienceJournal of Crohn's and Colitis 2012; 6(2): 143 doi: 10.1016/j.crohns.2011.07.011
11
Manfred Zierhut, Ahmet M. Abu El-Asrar, Bahram Bodaghi, Ilknur Tugal-Tutkun. Therapy of Ocular Behçet DiseaseOcular Immunology and Inflammation 2014; 22(1): 64 doi: 10.3109/09273948.2013.866257
12
Thomas R. Einarson, Basil G. Bereza, Xin Ying Lee, Filippo Lelli. Dose escalation of biologics in Crohn’s disease: critical review of observational studiesCurrent Medical Research and Opinion 2017; 33(8): 1433 doi: 10.1080/03007995.2017.1335001
13
Gregorio J. Martínez-Romero, Ana Alvariño, Esther Hinojosa, Maria Mora, Lorena Oltra, Nuria Maroto, Isabel Ferrer, María Dolores Hinojosa, Joaquin Ernesto Hinojosa. Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel diseaseRevista Española de Enfermedades Digestivas 2019; 111 doi: 10.17235/reed.2019.5600/2018
14
Laura Guberna, Olga P. Nyssen, María Chaparro, Javier P. Gisbert. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-AnalysisJournal of Clinical Medicine 2021; 10(10): 2132 doi: 10.3390/jcm10102132
15
Veerle JAA Nuij, Colin J de Haar, C Janneke van der Woude. Trial discontinuation: lessons for future trial design?Clinical Investigation 2012; 2(2): 147 doi: 10.4155/cli.11.185
16
Andreas Stallmach, Stefan Hagel, Tony Bruns. Adverse effects of biologics used for treating IBDBest Practice & Research Clinical Gastroenterology 2010; 24(2): 167 doi: 10.1016/j.bpg.2010.01.002
17
Hang Hock Shim, Cynthia H. Seow. Treatment of Inflammatory Bowel Disease with Biologics2018; : 141 doi: 10.1007/978-3-319-60276-9_10
18
Renato Caviglia, Ivo Boškoski, Michele Cicala. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issuesExpert Opinion on Drug Safety 2008; 7(5): 617 doi: 10.1517/14740338.7.5.617
19
J. P. Gisbert, A. C. Marín, M. Chaparro. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapyAlimentary Pharmacology & Therapeutics 2015; 42(4): 391 doi: 10.1111/apt.13276
20
Javier P Gisbert, Alicia C Marín, María Chaparro. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology 2016; 111(5): 632 doi: 10.1038/ajg.2016.54
21
Alfredo Adán, Victoria Hernandez, Santiago Ortiz, Juan Jose Molina, Laura Pelegrin, Gerard Espinosa, Raimon Sanmartí. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusionsInternational Ophthalmology 2010; 30(5): 577 doi: 10.1007/s10792-010-9372-1
22
Yu Nishida, Shuhei Hosomi, Kenji Watanabe, Kimihiko Watanabe, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Hirokazu Yamagami, Tetsuya Tanigawa, Toshio Watanabe, Yasuhiro Fujiwara. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitisScandinavian Journal of Gastroenterology 2018; 53(5): 579 doi: 10.1080/00365521.2017.1403647
23
Joana Torres, Ray K. Boyapati, Nicholas A. Kennedy, Edouard Louis, Jean-Frédéric Colombel, Jack Satsangi. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel DiseaseGastroenterology 2015; 149(7): 1716 doi: 10.1053/j.gastro.2015.08.055
24
Cátia Rocha, Paula Lago, Samuel Fernandes, Luís Correia, Francisco Portela, Ana Isabel Vieira, Marta Patita, Bruno Arroja, Paula Ministro, Catarina Alves, Cláudia Camila Dias, Fernando Magro. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassaysTherapeutic Advances in Gastroenterology 2020; 13: 175628482096579 doi: 10.1177/1756284820965790
25
David R. Minor, Kevin Chin, Mohammed Kashani-Sabet. Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related ColitisCancer Biotherapy and Radiopharmaceuticals 2009; 24(3): 321 doi: 10.1089/cbr.2008.0607
26
Maria H. Lönnkvist, Ragnar Befrits, Jon O. Lundberg, Joachim Lundahl, Ulrika L. Fagerberg, Henrik Hjortswang, Marianne van Hage, Per M. Hellström. Infliximab in clinical routine: experience with Crohnʼs disease and biomarkers of inflammation over 5 yearsEuropean Journal of Gastroenterology & Hepatology 2009; 21(10): 1168 doi: 10.1097/MEG.0b013e32832b125c
27
Maria Teresa Vietri, Gabriele Riegler, Marialaura De Paola, Serena Simeone, Maria Boggia, Alessia Improta, Mariarita Parisi, Anna Maria Molinari, Michele Cioffi. I219V Polymorphism in hMLH1 Gene in Patients Affected with Ulcerative ColitisGenetic Testing and Molecular Biomarkers 2009; 13(2): 193 doi: 10.1089/gtmb.2008.0088
28
N. Nazareth, F. Magro, J. Silva, M. Duro, D. Gracio, R. Coelho, R. Appelberg, G. Macedo, A. Sarmento. Infliximab therapy increases the frequency of circulating CD16+monocytes and modifies macrophage cytokine response to bacterial infectionClinical & Experimental Immunology 2014; 177(3): 703 doi: 10.1111/cei.12375
29
Jørgen Jahnsen, Trond Espen Detlie, Simen Vatn, Petr Ricanek. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational studyExpert Review of Gastroenterology & Hepatology 2015; 9(sup1): 45 doi: 10.1586/17474124.2015.1091308
30
J. LINDSAY, Y. S. PUNEKAR, J. MORRIS, G. CHUNG-FAYE. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease - modelling outcomes in active luminal and fistulizing disease in adultsAlimentary Pharmacology & Therapeutics 2008; 28(1): 76 doi: 10.1111/j.1365-2036.2008.03709.x
31
Marie Muller, Ferdinando D’Amico, Stefanos Bonovas, Silvio Danese, Laurent Peyrin-Biroulet. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic ReviewJournal of Crohn's and Colitis 2021; 15(5): 840 doi: 10.1093/ecco-jcc/jjaa186
32
M. Kraemer, A. Kirschmeier, T. Marth. Perioperative adjuvant therapy with infliximab in complicated anal crohn’s diseaseInternational Journal of Colorectal Disease 2008; 23(10): 965 doi: 10.1007/s00384-008-0500-6
33
Eun Suk Jung, Ko‐woon Choi, Seung Won Kim, Matthias Hübenthal, Sören Mucha, Jihye Park, Zewon Park, David Ellinghaus, Stefan Schreiber, Andre Franke, Woo Yong Oh, Jae Hee Cheon. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases Journal of Gastroenterology and Hepatology 2019; 34(10): 1727 doi: 10.1111/jgh.14652